Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict the shape of not only proteins but also DNA, RNA and other biological ...

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue on its mission to create new drugs and medicines using AI.

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

Decades ago, drug discovery was driven by trial and error in the lab. Today, the field has advanced alongside the rise of vast chemical, biological, and ...

A study published in Nature Chemistry by researchers from the University of Pittsburgh and Yale University shows how common ...

In the current study, the researchers used what is known as fragment-based drug design instead. The method involves first ...

New center will use cutting-edge AI to accelerate the creation of life-saving medicines AI Small Molecule Drug Discovery Center Photo 1 Left to Right: Ethan Grimes, BS, and Paul Morgan, MD, conduct ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

The event, held in the emblematic Casa de Convalescència, was supported by the BBVA Foundation and welcomed 150 international ...

A new study shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective.